Lyn Kamintsky

Lyn Kamintsky

Auto-generated profile, based on publicly available information

Lyn Kamintsky

Department of Medical Neuroscience, Dalhousie University, Halifax, Nova Scotia, Canada

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 2015 in Neurobiology of Disease
Verified
Journal Article
Closed access
IWItai Weissberg
Itai Weissberg
LWLydia Wood
Lydia Wood
LKLyn Kamintsky
Lyn Kamintsky
OVOscar Vazquez
Oscar Vazquez
DMDan Z. Milikovsky
Dan Z. Milikovsky
DKdaniela kaufer
daniela kaufer

21 March 2014 in Annals of Neurology
Verified
Journal Article
Closed access
PDF file
GBGuy Bar‐Klein
Guy Bar‐Klein
LCLuisa P. Cacheaux
Luisa P. Cacheaux
LKLyn Kamintsky
Lyn Kamintsky
OPOfer Prager
Ofer Prager
IWItai Weissberg
Itai Weissberg
AFAlon Friedman
Alon Friedman

23 April 2017 in Brain
Verified
Journal Article
Open access
PDF file
GBGuy Bar-Klein
Guy Bar-Klein
SLSvetlana Lublinsky
Svetlana Lublinsky
LKLyn Kamintsky
Lyn Kamintsky
INIris Noyman
Iris Noyman
RVRonel Veksler
Ronel Veksler
AFAlon Friedman
Alon Friedman
A biomarker that will enable the identification of patients at high-risk for developing post-injury epilepsy is critically required. Microvascular pathology and related blood–brain barrier dysfunction and neuroinflammation were shown to be associated with epileptogenesis after injury. Here we used prospective, longitudinal magnetic resonance imaging to quantitatively follow blood–brain barrier pathology in rats following status epilepticus, late electrocorticography to identify epileptic animals and post-mortem immunohistochemistry to confirm blood–brain barrier dysfunction and neuroinflammation. Finally, to test the pharmacodynamic relevance of the proposed biomarker, two anti-epileptogenic interventions were used; isoflurane anaesthesia and losartan. Our results show that early blood–brain barrier pathology in the piriform network is a sensitive and specific predictor (area under the curve of 0.96, P < 0.0001) for epilepsy, while diffused pathology is associated with a lower risk. Early treatments with either isoflurane anaesthesia or losartan prevented early microvascular damage and late epilepsy. We suggest quantitative assessment of blood–brain barrier pathology as a clinically relevant predictive, diagnostic and pharmaco!dynamics biomarker for acquired epilepsy.

1 January 2020 in NeuroImage: Clinical
Verified
Journal Article
Open access
LKLyna Kamintsky
Lyna Kamintsky
KCKathleen A. Cairns
Kathleen A. Cairns
RVRonel Veksler
Ronel Veksler
CBChris Bowen
Chris Bowen
SBSteven D. Beyea
Steven D. Beyea
CCCynthia Calkin
Cynthia Calkin
Bipolar disorder affects approximately 2% of the population and is typically characterized by recurrent episodes of mania and depression. While some patients achieve remission using mood-stabilizing treatments, a significant proportion of patients show progressive changes in symptomatology over time. Bipolar progression is diverse in nature and may include a treatment-resistant increase in the frequency and severity of episodes, worse psychiatric and functional outcomes, and a greater risk of suicide. The mechanisms underlying bipolar disorder progression remain poorly understood and there are currently no biomarkers for identifying patients at risk. The objective of this study was to explore the potential of blood-brain barrier (BBB) imaging as such a biomarker, by acquiring the first imaging data of BBB leakage in bipolar patients, and evaluating the potential association between BBB dysfunction and bipolar symptoms. To this end, a cohort of 36 bipolar patients was recruited through the Mood Disorders Clinic (Nova Scotia Health Authority, Canada). All patients, along with 14 control subjects (matched for sex, age and metabolic status), underwent contrast-enhanced dynamic MRI scanning for quantitative assessment of BBB leakage as well as clinical and psychiatric evaluations. Outlier analysis has identified a group of 10 subjects with significantly higher percentages of brain volume with BBB leakage (labeled the "extensive BBB leakage" group). This group consisted exclusively of bipolar patients, while the "normal BBB leakage" group included the entire control cohort and the remaining 26 bipolar subjects. Among the bipolar cohort, patients with extensive BBB leakage were found to have more severe depression and anxiety, and a more chronic course of illness. Furthermore, all bipolar patients within this group were also found to have co-morbid insulin resistance, suggesting that insulin resistance may increase the risk of BBB dysfunction in bipolar patients. Our findings demonstrate a clear link between BBB leakage and greater psychiatric morbidity in bipolar patients and highlight the potential of BBB imaging as a mechanism-based biomarker for bipolar disorder progression.

4 December 2019 in Science Translational Medicine
Verified
Journal Article
Closed access
PDF file
DMDan Z. Milikovsky
Dan Z. Milikovsky
JOJonathan Ofer
Jonathan Ofer
VSVladimir V. Senatorov
Vladimir V. Senatorov
AFAaron R. Friedman
Aaron R. Friedman
OPOfer Prager
Ofer Prager
AFAlon Friedman
Alon Friedman
Transient EEG slowing events are shared by patients and models of Alzheimer’s and epilepsy and are associated with blood-brain barrier dysfunction.

4 January 2019 in Epilepsia
Verified
Journal Article
Closed access
PDF file
OPOfer Prager
Ofer Prager
LKLyna Kamintsky
Lyna Kamintsky
LHLuisa A. Hasam‐Henderson
Luisa A. Hasam‐Henderson
KSKarl Schoknecht
Karl Schoknecht
VWVera Wuntke
Vera Wuntke
RKRichard Kovacs
Richard Kovacs